Alembic’s $12M UK Bet: Utility Therapeutics Acquisition Boosts Antibiotic Portfolio

Alembic Pharmaceuticals Ltd has made a strategic leap into the European infectious disease market by acquiring Utility Therapeutics Ltd, a UK-based specialty pharma firm, for $12 million. The acquisition was executed through Alembic’s wholly owned subsidiary and is aimed at strengthening its antibiotic pipeline, particularly in the urinary tract infection (UTI) segment.

 

Utility Therapeutics holds exclusive rights to two key drugs—oral pivmecillinam and intravenous mecillinam—which are already approved in several European countries and are undergoing regulatory review in the US. These antibiotics are considered effective against multi-drug resistant Gram-negative bacteria, a growing concern in global healthcare.

 

Key Highlights:

 

Deal Value: $12 million acquisition via Alembic’s overseas unit.

 

Target Company: Utility Therapeutics Ltd, UK-based antibiotic specialist.

 

Product Focus: Pivmecillinam and mecillinam for UTI and resistant bacterial infections.

 

Strategic Fit: Expands Alembic’s anti-infective portfolio and global footprint.

 

Regulatory Edge: Utility’s drugs are in advanced stages of USFDA review; EU approvals already in place.

 

Market Potential: Global UTI treatment market projected to exceed $10 billion by 2030.

 

Alembic aims to leverage Utility’s regulatory groundwork and clinical data to fast-track launches in regulated markets. The acquisition aligns with Alembic’s broader strategy to diversify its therapeutic offerings and deepen its presence in high-growth segments.

 

Sources: Alembic Pharmaceuticals Investor Relations, Economic Times, Business Standard